- Home
- OKYO vs DXR Comparison
OKYO vs DXR Comparison
Compare OKYO & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKYO | DXR |
|---|---|---|
| Founded | 2007 | 1970 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.3M | 71.4M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | OKYO | DXR |
|---|---|---|
| Price | $1.72 | $11.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $6.33 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 361.7K | 12.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.03 | $7.10 |
| 52 Week High | $3.35 | $14.76 |
Technical Indicators
Market Signals| Indicator | OKYO | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 43.36 | 36.19 |
| Support Level | $1.52 | $10.00 |
| Resistance Level | $2.25 | $11.32 |
| Average True Range (ATR) | 0.13 | 0.37 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 57.58 | 14.71 |
Price Performance
Historical ComparisonAbout OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.